FIRST-IN-MAN CLINICAL TRIAL OF INTRAPUTAMENAL CDNF IN PARKINSON’S DISEASE FINDS A CONSORTED BIOMARKER RESPONSE IN A SUBGROUP OF SUBJECTS
Objective: In the first-in-man clinical study of intermittent intraputamenal monthly infusions of CDNF in subjects with moderately advanced PD, we explored cerebrospinal fluid (CSF) biomarkers…Extensive volume increases sensitivity of alpha-synuclein accumulation in the gastrointestinal tract
Objective: This study aimed to verify whether evaluation of extensive tissue volume increases sensitivity of detecting alpha-synuclein (AS) pathology in the gastrointestinal (GI) tract in…Neurogenetic Traits Outline Vulnerability to Cortical Disruption in Parkinson’s Disease
Objective: In this study, we characterized the brain topological intersection between propagating connectivity networks in healthy controls (HC) and Parkinson’s disease (PD) participants and gene…Evaluating Engagement of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody to Physiological and Pathological Forms of Alpha-Synuclein for Phase 2 Dose Selection: A PBPK Modeling and Simulation Approach
Objective: To develop a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model to assist in the dose and dosing regimen selection of ABBV-0805 for Phase 2 studies. Background:…Elucidating multimodal endophenotypes of APOE-ε4 in α-synucleinopathies
Objective: To systematically identify phenotypes that consistently associate with the ε4-allele of apolipoprotein E (APOE-ε4) in α-synucleinopathies. Background: The APOE-ε4 presents an elevated risk not…A53T-SNCA-BAC transgenic mouse exhibits multiple prodromal symptoms of Parkinson’s disease: Gastrointestinal dysfunction, hyposmia and RBD-like behavior.
Objective: To develop biomarkers and disease-modifying therapies for Parkinson’s disease, an animal model that recapitulates the early phase of the disease is indispensable. The aim…Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody in Healthy Subjects
Objective: To evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of ABBV-0805 following administration of single ascending doses of ABBV-0805, administered as intravenous (IV) infusions…Plasma phosphorylated α-synuclein relates to cognitive impairment in patients with Parkinson’s disease
Objective: To investigate whether plasma phosphorylated α-synuclein (p-syn) were associated with cognitive function in Parkinson’s disease (PD). Background: Parkinson’s disease (PD) is the second most…The Prodromal PD study – multiple biomarkers for early diagnosis?
Objective: The study aims to deepen our understanding of the prodromal phase of Parkinson’s disease (PD) Background: At the time of PD diagnosis, nigrostriatal degeneration…Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1
Objective: To determine whether digital biomarker sensor data detect slowing in progression of core motor features of Parkinson’s disease (PD) in individuals with early PD…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 60
- Next Page »